Table 6 (a). Distribution of patients with and without adverse reactions in the azvudine group. (b). Distribution of patients with and without adverse reactions in the nirmatrelvir/ritonavir group
Underlying comorbidities (n,%) | Adverse reaction group (n = 186) | No adverse reaction group (n = 335) | P value |
|---|---|---|---|
Cardiovascular or cerebrovascular disease | 119 (64.0) | 193 (57.6) | 0.184 |
Diabetes mellitus | 42 (22.6) | 84 (25.1) | 0.596 |
Lung diseases | 25 (13.4) | 45 (13.4) | 1.000 |
Chronic kidney disease | 11 (5.9) | 18 (5.4) | 0.953 |
Chronic liver disease | 3 (1.6) | 21 (6.3) | 0.027 |
Rheumatologic diseases | 7 (3.8) | 33 (9.9) | 0.020 |
Malignant tumor | 36 (19.4) | 69 (20.6) | 0.822 |
Long-term use of immunosuppressive drugs | 35 (18.8) | 74 (22.1) | 0.443 |
Underlying comorbidities (n,%) | Adverse reaction group (n = 90) | No adverse reaction group (n = 117) | P value |
|---|---|---|---|
Cardiovascular or cerebrovascular disease | 66 (73.3) | 56 (47.9) | < 0.001 |
Diabetes mellitus | 23 (25.6) | 28 (23.9) | 0.916 |
Lung diseases | 16 (17.8) | 13 (11.1) | 0.243 |
Chronic kidney disease | 3 (3.3) | 5 (4.3) | 1.000 |
Chronic liver disease | 5 (5.6) | 5 (4.3) | 0.921 |
Rheumatologic diseases | 9 (10.0) | 6 (5.1) | 0.285 |
Malignant tumor | 12 (13.3) | 36 (30.8) | 0.005 |
Long-term use of immunosuppressive drugs | 17 (18.9) | 36 (30.8) | 0.075 |